RxDoctor Payments Data

Stephanie Lukaszka

Family · Cedar Rapids, IANPI 1073248316

Payments from drug & device makers

$2,164in general payments, 2019–2025

Across 85 payments — averaging $25.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Axonics, Inc.$423
  • Sumitomo Pharma America, Inc.$350
  • Astellas Pharma US Inc$270
  • 180 Medical, Inc.$224
  • Urogen Pharma, Inc.$168
  • Johnson & Johnson$106
  • plus $623 from 16 others

What the payments were for

  • Travel & lodging$1738%
  • Food & beverage$1,82584%
  • Education$1658%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,164 in reported general payments places this provider in the 90th percentile of 1,268 family providers in Iowa.

See all family providers in Iowa

Medicare billing

Part B allowed, 2024
$46,023
Medicare patients
235
Services billed
1,338

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron167$97,356
MyrbetriqMirabegron49$31,191
Estradiol76$5,854
Solifenacin Succinate119$5,003
Methenamine Hippurate52$3,679
Trospium Chloride15$1,414
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst49$880
Cephalexin147$776
Tamsulosin Hcl89$715
Trimethoprim17$592
Fesoterodine Fumarate ErFesoterodine Fumarate12$528
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim36$141
Oxybutynin Chloride ErOxybutynin Chloride11$134
Finasteride25$125
Metronidazole11$118

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$350$97,356167 claims
Astellas Pharma US IncMyrbetriq$270$31,19149 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,268 family providers in Iowa.

Other family in Cedar Rapids

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →